Business Context and Reporting Period
This Form 8-K is a current report filed by Greatbatch, Inc. (not Integer Holdings Corp) on October 13, 2011. The filing reports a corporate governance event: the election of a new director to the Board of Directors effective October 13, 2011.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Anthony P. Bihl III to the Board of Directors. Mr. Bihl will serve on the Corporate Governance & Nominating and Technology Development & Innovation Committees. His term lasts until the next annual meeting of stockholders.
Guidance, Outlook, and Management Commentary
There is no financial guidance or outlook provided in this filing. Management commentary is limited to highlighting Mr. Bihl's qualifications, including over 25 years of experience in the medical device industry in operations, finance, and general management. He is currently Group President of AMS (a subsidiary of Endo Pharmaceuticals) and previously served as CEO of AMS, Siemens Medical Solutions' Diagnostics Division, and President of Bayer HealthCare's Diagnostics Division.
Important Facts for Investors to Verify
- Confirm the effective date of Anthony P. Bihl III's directorship (October 13, 2011).
- Review the Company's most recent proxy statement (dated April 15, 2011) for details on the Director compensation program applicable to Mr. Bihl.
- Verify Mr. Bihl's current role as Group President of AMS, a subsidiary of Endo Pharmaceuticals.
- Note that this filing does not contain financial results; refer to the most recent 10-Q or 10-K for financial metrics.